Skip to content

US · CLGN · BIOTECHNOLOGY

CollPlant Biotechnologies Ltd. (CLGN) intrinsic value and stock valuation

$4.64as of 2026-11-21 · Mkt cap 4.02M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

CollPlant Biotechnologies Ltd. DCF and intrinsic value

InvestorsCraft values CLGN with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from CLGN’s statements →

CollPlant Biotechnologies Ltd. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Rehovot, TA 7670104 collplant.com

How the business is doing

Fiscal 2012–2025, USD

Revenue
$2.37M-17.3% 5y CAGRd
20122025
Net income
-$-11.49M
20122025
Free cash flow
-$-9.45M
20122025
Total equity
$6.08M+6.3% 5y CAGRd
20122025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2025, USD
20252024202320222021
Revenue$2.37M$520K$11M$300K$15.6M
Operating income-$-11.48M-$-17.25M-$-7.51M-$-17.1M$70K
Net income-$-11.49M-$-16.61M-$-7.02M-$-16.93M$240K
EPSd-$-941.8K-$-1.45M-$-616.33K-$-1.53M$20.1K
Operating cash flow-$-9.42M-$-14.09M-$-2.76M-$-13.7M$2.5M
Capital expenditure-$-30K-$-480K-$-950K-$-1.27M-$-1.43M
Free cash flow-$-9.45M-$-14.58M-$-3.72M-$-14.97M$1.07M
Total assets$10.8M$18.7M$34.1M$37.8M$51.2M
Total debt$2.85M$3.08M$3.16M$2.91M$3.61M
Net debt-$-3.1M-$-8.83M-$-23.52M-$-26.74M-$-9.54M
Total equity$6.08M$13.5M$28.3M$32.3M$45.1M
Cash and short-term investments$5.95M$11.9M$26.7M$29.7M$43.3M
Income statement
20252024202320222021
Revenue$2.37M$520K$11M$300K$15.6M
Cost of revenue$1.75M$2.66M$3.09M$1.48M$2M
Gross profit$620K-$-2.15M$7.87M-$-1.18M$13.6M
Research and development expenses$8.19M$10.5M$10.5M$10.3M$7.63M
Selling, general and administrative expenses$3.92M$4.59M$4.89M$5.67M$5.94M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$12.1M$15.1M$15.4M$15.9M$13.6M
Cost and expenses$13.9M$17.8M$18.5M$17.4M$15.6M
Interest income$380K$740K$790K$320K$220K
Interest expense$10K$20K$10K$30K$40K
Depreciation and amortization$910K$1.04M$1.1M$1.08M$770K
Ebitda-$-10.56M-$-15.55M-$-5.91M-$-15.81M$1.05M
Operating income-$-11.48M-$-17.25M-$-7.51M-$-17.1M$70K
Total other income/expenses, net-$-10K$640K$490K$170K$170K
Income before tax-$-11.49M-$-16.61M-$-7.02M-$-16.93M$240K
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-11.49M-$-16.61M-$-7.02M-$-16.93M$240K
Weighted average shares outstanding$12.2M$11.5M$11.4M$11M$9.97M
Weighted average diluted shares outstanding$12.2M$11.5M$11.4M$11M$12M
Balance sheet
20252024202320222021
Cash and short-term investments$5.95M$11.9M$26.7M$29.7M$43.3M
Net receivables$0.00$580K$390K$10K$270K
Inventory$570K$440K$710K$1.43M$1.08M
Total current assets$6.75M$13.2M$28M$31.7M$45.1M
Property, plant and equipment, net$3.89M$5.28M$5.86M$5.68M$5.68M
Goodwill and intangible assets$70K$130K$190K$240K$240K
Long-term investments$80K$120K$60K$190K$0.00
Total non-current assets$4.04M$5.53M$6.1M$6.11M$6.14M
Total assets$10.8M$18.7M$34.1M$37.8M$51.2M
Accounts payable$610K$870K$980K$1.13M$1.03M
Short-term debt$810K$810K$620K$530K$520K
Deferred revenue$0.00$0.00$0.00$0.00$30K
Total current liabilities$2.67M$2.97M$3.25M$3.1M$3.01M
Long-term debt$2.03M$2.27M$2.54M$2.38M$3.09M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$2.03M$2.27M$2.54M$2.38M$3.09M
Capital lease obligations$2.03M$3.08M$3.16M$2.91M$3.61M
Total liabilities$4.7M$5.25M$5.79M$5.49M$6.1M
Common stock$5.49M$4.98M$4.98M$4.87M$4.66M
Retained earnings-$-124.84M-$-113.35M-$-96.74M-$-89.72M-$-72.8M
Accumulated other comprehensive income (loss)-$-970K-$-970K-$-970K-$-970K-$-970K
Total equity$6.08M$13.5M$28.3M$32.3M$45.1M
Total investments$80K$120K$60K$190K$30.2M
Total debt$2.85M$3.08M$3.16M$2.91M$3.61M
Net debt-$-3.1M-$-8.83M-$-23.52M-$-26.74M-$-9.54M
Cash flow statement
20252024202320222021
Net income-$-11.49M-$-16.61M-$-7.02M-$-16.93M$240K
Depreciation and amortization$910K$1.04M$1.1M$1.08M$770K
Stock-based compensation$1M$1.72M$1.94M$2.17M$1.62M
Change in working capital$250K-$-260K$1M-$-610K$150K
Accounts receivable$360K-$-150K$10K$260K$560K
Inventory-$-130K$280K$750K-$-310K$180K
Accounts payable-$-260K$0.00$0.00$0.00$0.00
Net cash provided by operating activities-$-9.42M-$-14.09M-$-2.76M-$-13.7M$2.5M
Investments in property, plant and equipment-$-30K-$-480K-$-950K-$-1.27M-$-1.43M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-30K-$-540K-$-1.16M$28.9M-$-31.56M
Common stock issued$3.1M$0.00$0.00$0.00$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$3.1M$10K$1.11M$1.87M$38.8M
Net change in cash-$-6.21M-$-14.77M-$-3.19M$16.5M$9.85M
Cash at end of period$5.95M$11.9M$26.7M$29.9M$13.4M
Operating cash flow-$-9.42M-$-14.09M-$-2.76M-$-13.7M$2.5M
Capital expenditure-$-30K-$-480K-$-950K-$-1.27M-$-1.43M
Free cash flow-$-9.45M-$-14.58M-$-3.72M-$-14.97M$1.07M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About CollPlant Biotechnologies Ltd.

        CollPlant Biotechnologies Ltd. is a regenerative and aesthetic medicine enterprise operating across the United States, Canada, and Europe. The company primarily engages in the three-dimensional (3D) bioprinting of tissues and organs, alongside developing solutions for medical aesthetics. All of CollPlant's offerings are underpinned by its proprietary plant-based genetic engineering technology, which facilitates the production of recombinant type I human collagen. Its diverse product portfolio encompasses BioInks engineered for 3D tissue and organ fabrication; dermal and soft tissue fillers designed to diminish wrinkles; and innovative breast implants, both 3D bioprinted and injectable, aimed at promoting breast tissue regeneration. CollPlant also provides a 3D bioprinted regenerative soft tissue matrix. Specialized products include VergenixSTR, a soft tissue repair matrix targeting tendinopathy, and VergenixFG, an advanced wound care treatment for deep surgical incisions and persistent wounds such as diabetic, venous, and pressure ulcers, burns, and bedsores. The company maintains strategic collaboration agreements with numerous partners, including 3D Systems Corporation, CellInk (a BICO Group company), the Advanced Regenerative Manufacturing Institute, the RegenMed Development Organization, Israel's Technion Institute of Technology, AbbVie, and STEMCELL. Established in Rehovot, Israel, in 2004, the company was formerly known as CollPlant Holdings Ltd. before adopting its current name in June 2019.

        CEO
        Yehiel Tal
        Employees
        39
        Beta
        0.65

        Explore

        Frequently asked questions

        What is the intrinsic value of CollPlant Biotechnologies Ltd. (CLGN)?

        CollPlant Biotechnologies Ltd. (CLGN) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is CLGN undervalued?

        CLGN trades at a price of $4.64 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.